Evolving Treatment Paradigms For Rheumatoid ArthritisTranslating Comprehensive Patient Evaluations Into Personalized Therapy
November 2017; San Diego, California.
Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice.
Anderson J et al. Arthritis Care Res (Hoboken). 2012;64(5):640-647.
Methotrexate and rheumatoid arthritis: current evidence regarding subcutaneous versus oral routes of administration.
Bianchi G, et al. Adv Ther. 2016;33(3):369-378.
Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial.
Burmester GR, et al. Ann Rheum Dis. 2017;76(5):840-847.
Burmester GR, et al. Ann Rheum Dis. 2016;75(6):1081-1091.
Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials.
Cohen SB, et al. Ann Rheum Dis. 2017;76(7):1253-1262.
Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study.
Dougados M, et al. Ann Rheum Dis. 2017;76(1):88-95.
Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, aglobal, observational, comparative effectiveness study.
Emery P, et al. Ann Rheum Dis. 2015;74(6):979-984.
Sarilumab and nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis and inadequate response or intolerance to tumor necrosis factor inhibitors.
Fleischmann R, et al. Arthritis Rheumatol. 2017;69(2):277-290.
Improvements in remission and low disease activity are achieved with ongoing sarilumab treatment, in patients with rheumatoid arthritis in 2 phase 3 studies.
Genovese MC, et al. Arthritis Rheumatol. 2017;69(suppl 10):Abstract 2480.
Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial.
Fleischmann R, et al. Lancet. 2017;390(10093):457-468.
Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a phase III study.
Genovese MC, et al. Arthritis Rheumatol. 2015;67(6):1424-1437.
Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study.
Jones G, et al. Ann Rheum Dis. 2010;69(1):88-96.
Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2).
Kavanaugh A, et al. Ann Rheum Dis. 2017;76(6):1009-1019
Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year.
Kremer JM, et al. Arthritis Rheum. 2011;63(3):609-621.
Cycling versus swapping in patients with rheumatoid arthritis with an inadequate response to at least one tumor necrosis factor alpha inhibitor: asystematic review and meta-analysis of observational study.
Lopez-Olivo MA, et al. Arthritis Rheumatol. 2017;69(suppl 10):Abstract 2483.
McInnes IB, Schett G. Lancet. 2017;389(10086):2328-2337.
Power Doppler ultrasonography detects superior efficacy of non-TNF biologics compared to cycling of TNF inhibitors in RA patients’ inadequate response to first TNF inhibitors.
Nishino A, et al. Arthritis Rheumatol. 2017;69(suppl 10):Abstract 238.
Sarilumab improves patient-reported outcomes in rheumatoid arthritis patients with inadequate response/intolerance to tumour necrosis factor inhibitors.
Strand V, et al. RMD Open. 2017;3(1):e000416.
Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial.
Strand V, et al. Arthritis Res Ther. 2016;18:198.
Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1).
Westhovens R, et al. Ann Rheum Dis. 2017;76(6):998-1008.
New Horizons in RA Therapy From the 2017 ACR/ARHP Annual Meeting
Improved Diagnostic and Management Strategies
Long-Term Management Strategies to Improve Patient Outcomes
Evidence-Based Strategies for Improved Patient Outcomes
Evolving Strategies for Diagnosis and Long-Term Management
Treating to Target, IL-6-Directed Therapies, and Evolving Management Algorithms
Evolving Treatment Algorithms and Expert Perspectives on Biosimilars
Pathophysiology to the Management of Moderate-to-Severe Disease
Targeting Immune Dysregulation and Delivering Comprehensive Care
Looking Beyond Barriers to Optimize Therapy
New Perspectives on Targeting Remission and Individualizing Therapy
Using Imaging to Improve Patient Outcomes
Discussions and Debates on the Evolving Roles of Targeted Synthetic DMARDs
Translating Pathophysiology into Targeted Treatments
Think You Know JAK?
An Interactive Experience Highlighting Recent Clinical Advances
Debates & Discussions on the Evolving Role of JAK Inhibitors
The Evolving Role of JAK Inhibitors
Unpacking the Evidence for Their Use Today and Tomorrow
Unlocking Novel Paths to Patient Care
The Increasing Role of JAK Inhibitors
Unlocking Novel Paths to Patient Care
New Pathways to Patient Management
A Focus on Clinical Evidence and Guideline Recommendations
New Avenues to the Management of Severe Asthma
Interdisciplinary Strategies for Adult and Pediatric Patients